PMID- 37812992
OWN - NLM
STAT- MEDLINE
DCOM- 20231110
LR  - 20231110
IS  - 1873-3727 (Electronic)
IS  - 0001-8686 (Linking)
VI  - 321
DP  - 2023 Nov
TI  - Core-shell inorganic NP@MOF nanostructures for targeted drug delivery and 
      multimodal imaging-guided combination tumor treatment.
PG  - 103007
LID - S0001-8686(23)00174-4 [pii]
LID - 10.1016/j.cis.2023.103007 [doi]
AB  - It is well known that metal-organic framework (MOF) nanostructures have unique 
      characteristics such as high porosity, large surface areas and adjustable 
      functionalities, so they are ideal candidates for developing drug delivery 
      systems (DDSs) as well as theranostic platforms in cancer treatment. Despite the 
      large number of MOF nanostructures that have been discovered, conventional 
      MOF-derived nanosystems only have a single biofunctional MOF source with poor 
      colloidal stability. Accordingly, developing core-shell MOF nanostructures with 
      good colloidal stability is a useful method for generating efficient drug 
      delivery, multimodal imaging and synergistic therapeutic systems. The preparation 
      of core-shell MOF nanostructures has been done with a variety of materials, but 
      inorganic nanoparticles (NPs) are highly effective for drug delivery and 
      imaging-guided tumor treatment. Herein, we aimed to overview the synthesis of 
      core-shell inorganic NP@MOF nanostructures followed by the application of 
      core-shell MOFs derived from magnetic, quantum dots (QDs), gold (Au), and 
      gadolinium (Gd) NPs in drug delivery and imaging-guided tumor treatment. 
      Afterward, we surveyed different factors affecting prolonged drug delivery and 
      cancer therapy, cellular uptake, biocompatibility, biodegradability, and enhanced 
      permeation and retention (EPR) effect of core-shell MOFs. Last but not least, we 
      discussed the challenges and the prospects of the field. We envision this article 
      may hold great promise in providing valuable insights regarding the application 
      of hybrid nanostructures as promising and potential candidates for multimodal 
      imaging-guided combination cancer therapy.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Khan, Suliman
AU  - Khan S
AD  - Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Falahati, Mojtaba
AU  - Falahati M
AD  - Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC 
      Cancer Institute, Erasmus MC, Rotterdam, the Netherlands; Nanomedicine Innovation 
      Center Erasmus (NICE), Erasmus MC, Rotterdam, the Netherlands. Electronic 
      address: m.falahati@erasmusmc.nl.
FAU - Cho, William C
AU  - Cho WC
AD  - Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong 
      SAR, China.
FAU - Vahdani, Yasaman
AU  - Vahdani Y
AD  - Department of Biochemistry and Molecular Medicine, University of Montreal, 
      Canada.
FAU - Siddique, Rabeea
AU  - Siddique R
AD  - Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Sharifi, Majid
AU  - Sharifi M
AD  - Student Research Committee, School of Medicine, Shahroud University of Medical 
      Sciences, Shahroud, Iran; Department of Tissue Engineering, School of Medicine, 
      Shahroud University of Medical Sciences, Shahroud, Iran.
FAU - Jaragh-Alhadad, Laila Abdulmohsen
AU  - Jaragh-Alhadad LA
AD  - Department of Chemistry, College of Science, Kuwait University, Safat 13060, 
      Kuwait.
FAU - Haghighat, Setareh
AU  - Haghighat S
AD  - Department of Microbiology, Faculty of Advanced Sciences and Technology, Tehran 
      Medical Sciences, Islamic Azad University, Tehran, Iran.
FAU - Zhang, Xiaoju
AU  - Zhang X
AD  - Department of Respiratory and Critical Care Medicine, Henan Provincial People's 
      Hospital, Zhengzhou, China.
FAU - Ten Hagen, Timo L M
AU  - Ten Hagen TLM
AD  - Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC 
      Cancer Institute, Erasmus MC, Rotterdam, the Netherlands; Nanomedicine Innovation 
      Center Erasmus (NICE), Erasmus MC, Rotterdam, the Netherlands. Electronic 
      address: t.l.m.tenhagen@erasmusmc.nl.
FAU - Bai, Qian
AU  - Bai Q
AD  - Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China. Electronic address: baiqian@zzu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230925
PL  - Netherlands
TA  - Adv Colloid Interface Sci
JT  - Advances in colloid and interface science
JID - 8706645
RN  - 0 (Metal-Organic Frameworks)
SB  - IM
MH  - Humans
MH  - *Metal-Organic Frameworks/chemistry
MH  - Drug Delivery Systems
MH  - *Neoplasms/diagnostic imaging/drug therapy/pathology
MH  - *Nanostructures
MH  - Multimodal Imaging
OTO - NOTNLM
OT  - Cancer therapy
OT  - Core-shell metal-organic framework
OT  - Drug delivery
OT  - Imaging
COIS- Declaration of Competing Interest The authors declare no conflict of interest.
EDAT- 2023/10/10 00:42
MHDA- 2023/11/10 06:45
CRDT- 2023/10/09 18:37
PHST- 2022/10/14 00:00 [received]
PHST- 2023/08/16 00:00 [revised]
PHST- 2023/09/23 00:00 [accepted]
PHST- 2023/11/10 06:45 [medline]
PHST- 2023/10/10 00:42 [pubmed]
PHST- 2023/10/09 18:37 [entrez]
AID - S0001-8686(23)00174-4 [pii]
AID - 10.1016/j.cis.2023.103007 [doi]
PST - ppublish
SO  - Adv Colloid Interface Sci. 2023 Nov;321:103007. doi: 10.1016/j.cis.2023.103007. 
      Epub 2023 Sep 25.